Stock VRPX VIRPAX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-04-29 EDT 		5-day change 1st Jan Change
2.77 USD -10.65% Intraday chart for Virpax Pharmaceuticals, Inc. -16.06% -13.46%
03-26 Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-15 Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Virpax Pharmaceuticals Reports 2023 Year-End Results
BU
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs
MT
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price
AQ
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
BU
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
BU
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
BU
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research
CI
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall
MT
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
BU
Virpax Pharmaceuticals : Failure to Satisfy Listing Rule - Form 8-K
PU
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
AQ
Virpax Pharmaceuticals Announces Leadership Transition
AQ
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
BU
 Virpax Pharmaceuticals Announces Leadership Transition
BU
Virpax Pharmaceuticals Announces Leadership Transition
CI
Virpax Pharmaceuticals, Inc. Announces CEO Changes
CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
BU
Virpax Pharmaceuticals Announces that Envelta Remains on Track for Trial in Humans Following FDA Review
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRPX Stock
  4. News Virpax Pharmaceuticals, Inc.